U.S. markets close in 5 hours 50 minutes
  • S&P 500

    3,788.00
    +19.75 (+0.52%)
     
  • Dow 30

    30,913.54
    +99.28 (+0.32%)
     
  • Nasdaq

    13,114.99
    +116.49 (+0.90%)
     
  • Russell 2000

    2,143.35
    +20.15 (+0.95%)
     
  • Crude Oil

    52.68
    +0.32 (+0.61%)
     
  • Gold

    1,834.00
    +4.10 (+0.22%)
     
  • Silver

    25.15
    +0.28 (+1.12%)
     
  • EUR/USD

    1.2127
    +0.0044 (+0.36%)
     
  • 10-Yr Bond

    1.1140
    +0.0170 (+1.55%)
     
  • GBP/USD

    1.3620
    +0.0034 (+0.25%)
     
  • USD/JPY

    104.0020
    +0.3150 (+0.30%)
     
  • BTC-USD

    37,036.17
    +594.43 (+1.63%)
     
  • CMC Crypto 200

    732.84
    +17.64 (+2.47%)
     
  • FTSE 100

    6,699.20
    -21.45 (-0.32%)
     
  • Nikkei 225

    28,633.46
    +391.25 (+1.39%)
     

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cantel Medical Corp.

·2 min read

NEW YORK, Jan. 12, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cantel Medical Corp. ("CMD" or the "Company") (NYSE: CMD) in connection with the proposed acquisition of the Company by STERIS plc ("STERIS") (NYSE: STE). Under the terms of the merger agreement, STERIS will acquire CMD in a mixed cash-and-stock transaction, pursuant to which CMD shareholders will receive $16.93 in cash and 0.33787 of a STERIS ordinary share for each CMD share that they own, representing implied per-share merger consideration of approximately $84.66 based upon STERIS' January 11, 2021 closing price of $200.46.

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)
WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you own CMD shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslawllp.com/CMD/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

WeissLaw LLP is investigating whether CMD's board acted in the best interest of CMD's public shareholders in agreeing to the proposed transaction, whether the merger consideration adequately compensates CMD's shareholders, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to CMD's public shareholders. Notably, at least one analyst has set a price target for the company of $100.00, approximately $15.00 above the implied per-share merger consideration.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-cantel-medical-corp-301206937.html

SOURCE WeissLaw LLP